Anti-cyclic citrullinated peptide antibody versus HAQ/MDHAQ: Comparing apples and oranges?

Journal of Rheumatology

Volumn 36, Issue 8, 2009, Pages 1565-1567

  Bykerk, Vivian ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR;

CLINICAL DECISION MAKING; CLINICAL EXAMINATION; COMORBIDITY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; EDITORIAL; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT RADIOGRAPHY; LOW DRUG DOSE; MORTALITY; MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HEALTH STATUS; HUMANS; PEPTIDES, CYCLIC; QUESTIONNAIRES; RHEUMATOLOGY;

EID: 68849103216     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090673     Document Type: Editorial

References (15)

1. Pincus T, Yazici Y, Bergman MJ. Quantitative clinical rheumatology: Why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool? J Rheumatol 2009;36:1563-4.
2. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
3. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
4. Van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized, placebo controlled trial. Arthritis Rheum 2007;56:1424-32.
5. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
6. Smolen JS, van der Heijde DMFM, St. Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
7. Sihvonen S, Korpela M, Mustila A, et al. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 2005;32:2089-94.
8. Bossuyt X, Coenen D, Fieuws S, Verschueren P, Westhovens R, Blanckaert N. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis 2009;68:287-9.
9. Liao KP, Batra KL, Chibnik L, Schur PH, Costenbader KH. Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 2008;67:1557-61.
10. De Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008;58:1293-8.
11. Bukhari M, Thomson W, Naseem H, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Rheum 2007;56:2929-35.
12. van der Woude D, Young A, Brand R, et al. Prevalence and predictive factors for DMARD-free remission in RA. Lessons from 2 large early arthritis cohorts [abstract]. Arthritis Rheum 2008;58 Suppl:S760.
13. Fransen J, Lann RFJM, van der Laar MAFJ, et al. Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis. Ann Rheum Dis 2004;63;1222-6.
14. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008;66:216-23.
15. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.